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Lidocaine, bupivacaine or ropivacaine are routinely used to manage 
perioperative pain. Sparse data exist focusing on the effects of local anesthetics 
(LA) on fibroblasts, which are actively involved in wound healing. Therefore, we 
investigated the effects of the three LA to assess survival, viability and 
proliferation rate of fibroblasts. Human fibroblasts were exposed to 0.3 mg/ml 
and 0.6 mg/ml of each LA for 2 days, followed by an incubation with normal 
medium for another 1, 4 or 7 days (group 1). Alternatively, cells were 
permanently incubated with LA for 3, 6 or 9 days (group 2). Live cell count was 
assessed using trypan blue staining. Viability was measured by the tetrazolium 
bromide assay, proliferation tests were performed with the help of the 
colorimetric bromodeoxyuridine assay. Production of reactive oxygen species 
(ROS) was determined, measuring the oxidation of non-fluorescent-2,7’-
dichlorofluorescin. Treatment of cells with the three LA showed a concentration-
dependent decrease of live cells, mitochondrial activity, and proliferation rate. 
Group arrangement played a significant role for cell count and proliferation, while 
exposure time influenced viability. Among the analyzed LA, bupivacaine showed 
the most severe cytotoxic effects. Increased production of ROS correlated with 
decreased viability of fibroblasts in lidocaine- and bupivacaine-exposed cells, but 
not upon stimulation with ropivacaine. This study shows a concentration-
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dependent cytotoxic effect of lidocaine, bupivacaine and ropivacaine on 
fibroblasts in vitro with more pronounced effects after continuous incubation. A 
possible mechanism of cell impairment could be triggered by production of ROS 




Pain control with local anesthetics is a major issue in perioperative medicine. 
Local anesthetics (LA) are topically injected (such as intraarticular application) or 
applied through a perineural or wound catheter for pain management [1-7]. 
Clinically used concentrations of LA vary from 2 mg/ml to 10 mg/ml, depending 
on the chosen type and duration of analgesia. 
Lidocaine, bupivacaine and ropivacaine are all amide type local 
anesthetics. Recent publications have suggested potential adverse effects of 
lidocaine, bupivacaine and ropivacaine on articular chondrocytes in vitro [8-10]. 
Moreover, studies have also shown toxic effects of local anesthetics on tissues 
which are involved in postoperative recovery and wound healing, challenging the 
safe continuous application of local anesthetics in clinical practice [11,12]. 
Wound healing after surgery is a natural process of regenerating tissue. A 
set of complex biochemical events takes place in a closely orchestrated cascade 
to repair tissue. These events overlap in time and may be artificially categorized 
into 3 steps: inflammatory, proliferative and remodeling phase. Fibroblasts play a 
crucial role in the proliferative phase. They migrate from normal tissue into the 
wound area from its margins, where they grow and form a new, provisional 
extracellular matrix by excreting collagen and fibronectin. 
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 Due to the crucial role of fibroblasts in the wound healing process, we 
investigated the effects of different concentrations of local anesthetics on viability 
and proliferation of fibroblasts. Based on previous results in an inflammatory 
model of acute lung injury [13], we hypothesized that local anesthetics do not 
have an adverse effect on fibroblasts. 
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MATERIAL and METHODS 
 
Fibroblasts 
In this study, human osteosarcoma cells (LGC Standard GmbH, Wesel, 
Germany), an osteoblast-like cell type with the morphology of human fibroblasts 
were used. According to a study from Jukkola et al. in 1993, these cells have the 
characteristics of proliferative wound fibroblasts [14]. Cells were cultured in α-
modified eagle medium (MEM, LGC Standard GmbH, Wesel, Germany) with 
10% fetal bovine serum (FBS, LGC Standard GmbH) and 10'000 U/l 
penicillin/streptomycin (LGC Standard GmbH) at 37ºC and 5% CO2. 
 Lidocaine (Lidocain CO2 2% Sintetica®) was purchased from Sintetica 
AG, Mendrisio, Switzerland, bupivacaine (Bucain®) from DeltaSelect GmbH, 




Serial dilutions were chosen with lidocaine, bupivacaine and ropivacaine 
resulting in concentrations of 0.3 mg/ml and 0.6 mg/ml, representing comparable 
tissue concentrations measured in clinical practice [15]. 
 In group 1, cells were exposed to the LA for 2 days followed by another 
incubation time of 1, 4 or 7 days with normal medium without LA. In group 2, 
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cells were permanently exposed to local anesthetics for 3, 6 or 9 days. The LA-
containing medium was changed every second day to provide stable and 
constant drug concentrations. 
 Control cells were incubated with medium only for the according period of 
time. All changes of medium performed in the treated group were similarly done 
in control cells.  
 
Cell count 
On day 3, 6 and 9, living cells were counted manually in the Neubauer chamber, 
using trypan blue [16,17]. 
 
Cell viability 
The tetrazolium bromide (MTT) assay is a well-known and recognized method to 
measure cell viability in vitro.18 The method is based on the reduction of the 
yellow tetrazoliumsalt 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium 
bromide into purple formazan crystals by mitochondrial dehydrogenases. 
Dehydrogenases are active in living cells only. Conversion of MTT is therefore 
directly related to cell viability. 
 
Cell proliferation 
Proliferation tests were performed with the help of the colorimetric 
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bromodeoxyuridine (BrdU) assay (Roche, Basel, Switzerland). The test analyzes 
the proliferation of cells by utilizing BrdU as an analog of the DNA nucleotide 
thymidine, which is incorporated into the synthesized DNA of actively dividing 
cells. The amount of BrdU incorporation is reflected in the intensity of 
absorbance of the final reaction, measured with an ELISA-Reader at 450 nm 
(reference wavelength 620 nm) [19,20]. 
  
Fluorometric assays for determination of caspase-3 activity  
Caspase-3 activity was determined by measuring proteolytic cleavage of the 
fluorogenic caspase-3 substrate Ac-Asp-Glu-Val-Asp-AMC (Calbiochem, 
Laeufelfingen, Switzerland). Cells were incubated for 1 hour at 37ºC with 2,5 µM 
substrate. The fluorescence of the cleaved reporter group was measured at an 
excitation wavelength of 360 nm and an emission wavelength of 465 nm.  
 
Determination of reactive oxygen species (ROS) 
To quantify possible ROS generation by fibroblasts, experiments were performed 
measuring the oxidation of non-fluorescent 2,7’-dichlorofluorescin (DCFH) 
(Sigma, Buchs, Switzerland) substrate to highly fluorescent DCF by ROS. As the 
experimental setup could only be performed for a short exposure, LA were 
incubated for 5 hours with fibroblasts. Cells were loaded with DCFH during a 60-
min incubation in Hanks Balanced Salt Solution (HBSS, Sigma, Buchs, 
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Switzerland) supplemented with 30 mM glucose (D-(+)-Glucose (Sigma, Buchs, 
Switzerland), pH 7.4, and 50 µM DCFH-DA (Sigma, Buchs, Switzerland) at room 
temperature in the dark. Cells were washed three times with HBSS to remove 
any extracellular probe from the extracellular environment. Thereafter, cells were 
exposed to various concentrations of local anesthetics in HBSS. The amount of 
generated DCF was measured using a fluorescence Synergy HT (Bio-TEK, 
Winooski, VT). The excitation filter was set at 485 nm, the emission filter was set 
at 530 nm. At the same time, cell viability and activity of caspase-3 were 
determined as well. 
 
Statistical analysis 
Values were expressed as mean ± SD. Results are presented in percentage to 
control. Cell count and ELISA data regarding viability, proliferation rate, and 
caspase-3 activity were analyzed using three-way ANOVA. Pearson’s product 
moment correlation coefficients were computed between ELISA results regarding 
production of reactive oxygen species and cell viability. OriginPro 8G (OriginLab, 
Northampton, MA, USA) and SPSS (SPSS, Inc., Chicago, IL) were used for 






In group 1, no negative effect of lidocaine and ropivacaine regarding cell survival 
was observed for the concentration of 0.3 mg/ml (Fig. 1A). In the presence of 
bupivacaine cell death ranged between 20% and 40%. With the concentration of 
0.6 mg/ml, cell survival in the lidocaine and ropivacaine group was similar with 
50% to 90%, while a prominent effect on cell death rate was observed for 
bupivacaine with 30% survival after 3 days, 5% after 6 days and no survival after 
9 days of incubation (Fig. 1B). 
In group 2 with a permanent incubation of fibroblasts with LA at a 
concentration of 0.3 mg/ml, cell survival of 70%-80% upon time was found for 
lidocaine and ropivacaine. Cell death was more evident in the bupivacaine group, 
showing a time-dependent decrease of survival (Fig. 1C). For the concentration 
of 0.6 mg/ml, cell survival decreased over time with no major differences 
between the three LA (Fig. 1D). 
Concentration of lidocaine, bupivacaine and ropivacaine has a significant 
effect on cell death (for lidocaine p< 0.001, bupivacaine p< 0.001, and 
ropivacaine p=0.001). Group arrangement significantly influences cell survival as 




Cell viability determined in fibroblasts from group 1 showed a similar pattern as 
trypan blue assays: only minor impairment over time was observed for the three 
LA with the concentration of 0.3 mg/ml (Fig. 2A). While viability was not 
diminished after incubation with lidocaine and ropivacaine in a concentration of 
0.6 mg/ml, MTT decreased time-dependently after incubation with bupivacaine 
(Fig. 2B).  
In group 2, MTT did not change upon incubation with lidocaine and 
ropivacaine with the lower concentration. However, no cells survived after 9 days 
of bupivacaine exposure (Fig. 2C). With the higher concentration, fibroblasts 
experienced serious impairment of viability with increasing time of exposure. The 
most pronounced effect was observed in the bupivacaine group (Fig. 2D).  
Correlation analysis revealed a time- and concentration-dependent effect 
on cell viability for all three LA with the following values: Lidocaine time p=0.019, 
concentration p< 0.001; bupivacaine time p=0.05, concentration p< 0.001; 
ropivacaine time p=0.004, concentration p< 0.001. An effect based on the type of 
stimulation (group 1 or 2) was not observed. 
 
Proliferation rate 
Thymidine incorporation over time upon incubation with each of the three LA was 
not changed after exposure to a low concentration of LA (Fig. 3A). With the 
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concentration of 0.6 mg/ml, again proliferation rate was only decreased in the 
bupivacaine group (Fig. 3B). 
In group 2 with continued incubation with the low concentration of LA, 
proliferation rate decreased to 80% in the lidocaine and ropivacaine group (Fig. 
3C). This effect was more pronounced with the concentration of 0.6 mg/l. 
Bupivacaine had with both concentrations a more pronounced effect on 
thymidine incorporation compared to the two other LA (Fig. 3D). 
Concentration of the LA has a statistical significant impact on proliferation 
rate (lidocaine: p< 0.001, bupivacaine: p< 0.001, ropivacaine p=0.001) as well as 
had the group constellation (lidocaine: p< 0.001, bupivacaine: p=0.009, 
ropivacaine p=0.001).  
 
Apoptosis rate  
Apoptosis of fibroblasts was determined upon exposure to lidocaine, bupivacaine 
and ropivacaine. In group 1, apoptosis rate was diminished for all 3 LA in a 
similar way for both concentrations (Fig. 4A, B). 
With permanent incubation with LA apoptosis rate decreased in a time- 
and concentration dependent fashion for lidocaine. An increase of the apoptosis 
rate was observed at 3 days of incubation with the concentration of 0.3 mg/ml 
(bupivacaine, ropivacaine) and 0.6 mg/ml (ropivacaine) (Fig. 4C and 4D). 
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Calculations regarding the influence of incubation time, concentration of 
LA and group arrangement on apoptosis only reached statistical significance for 
lidocaine with p< 0.001 for concentration and p=0.006 for group.  
 
Production of ROS 
The possibility of LA-induced expression of ROS was assessed. This could lead 
to an increased rate of cell death. Production of ROS after short time incubation 
(5 hours) with lidocaine or bupivacaine was enhanced with increasing 
concentrations from 0.3 mg/ml, 0.6 mg/ml to 1.3 mg/ml (Fig. 5A). For 
ropivacaine, no production of ROS was observed. After incubation with lidocaine 
and bupivacaine a decrease of viability was measured, while viability of 
fibroblasts was not impaired in the presence of ropivacaine (Fig. 5B). Viability of 
fibroblasts negatively correlated with production of ROS (Fig. 6A, B). The highest 
correlation was observed in the bupivacaine group (Pearson correlation of -0.74) 
(Tab. 1), while the correlation value for lidocaine was -0.53. As no ROS were 
generated in the presence of ropivacaine, correlation coefficient was not relevant 
for this LA. Caspase-3 activity did not increase upon short term incubation with 





This in vitro study shows a cytotoxic effect of lidocaine, bupivacaine and 
ropivacaine on fibroblasts. In group 1 with exposure to local anesthetics for 2 
days, followed by a incubation with normal medium, cells were only slightly 
impaired upon stimulation with lidocaine and ropivacaine. However, bupivacaine 
had a significant concentration-dependent impact. In group 2, where fibroblasts 
were permanently exposed to LA, cells were impaired time- and concentration-
dependently with all LA. The most negative effect was observed after exposure 
to bupivacaine. We assume that single injections do not impair the tissue. 
Compared to previous investigations the present study is original because: 
1. Three different local anesthetics were tested, 2. Experiments were performed 
in cell culture of human fibroblasts, 3. Different concentrations of LA were 
evaluated, 4. Different incubation periods were assessed. 5. A possible 
mechanism of cytotoxicity was tested. This broad and carefully designed 
approach allows drawing detailed conclusions concerning would healing in the 
presence of LA. 
Previous experiments have demonstrated a possible impairment of the 
proliferation rate of cells such as type II pneumocytes or endothelial cells [21,22]. 
These data reflected rather the impact of local anesthetics in very low 
concentrations as found in the respiratory or vascular compartment. Our study, 
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however, focused on concentrations as observed after injection into a wound 
area. A retrospective analysis of shoulder arthroscopy with intraarticular bolus 
injection of 0.25% bupivacaine with epinephrine described chondrolysis as a 
devastating complication [23]. A direct causative correlation between 
chondrolysis and application of local anesthetics could not be shown, but the 
authors strongly advised against the use of large doses of intra-articular 
placement of local anesthetics [23]. The use of topical corneal anesthetics for 
pain relief after corneal abrasion seems to have limited use as well [24]: Bisla et 
al. have examined epithelial regeneration in the presence of lidocaine 100 – 1000 
µg/ml, and have observed a dose-dependent impairment of epithelial wound 
healing with concentrations higher than 250 µg/ml, which would also point out the 
negative effect of LA [24]. All these studies pointed out a potential harm using 
local anesthetics, but did not specify the exact mechanism of impairment. 
Results from our study confirm other experimental findings, demonstrating 
that bupivacaine has a higher toxicity potential compared to lidocaine and 
ropivacaine [25,26]. In addition, it also corroborates the results from Sturrock et 
al., demonstrating a compromised cell survival in hamster lung fibroblasts with an 
ED50 of 0.06% for bupivacaine compared to 0.09% for lidocaine [27]. 
The present study suggests that the observed cell death is not mainly due 
to increased apoptosis rate since activity of caspase-3 was significantly 
correlated to the amount of living cells. An exception was observed for the short 
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stimulation period of 3 days for bupivacaine and ropivacaine. Caspase-
independent mechanisms of cell death have been described in LA-induced 
cytotoxicity due to a change in intracellular Ca2+ homeostasis [28-33]. It is 
postulated in myocytes that LA induce Ca2+ release from the sarcoplasmic 
reticulum by interaction with ryanodine receptors [34,35]. Other studies 
suggested an inhibition of Ca2+ reuptake into the sarcoplasmic reticulum, 
regulated by Ca2+ ATPase activity [35,36]. Beside dysregulated intracellular Ca2+ 
the involvement of production of ROS is another possible mechanism of LA-
induced cell death [37,38]. As described for cocaine, LA and/or its oxidative 
metabolites might trigger the release of ROS, which have a toxic effect on 
hepatocytes [37,38]. Other authors claimed a correlation between the 
dysregulation of mitochondrial Ca2+ and production of ROS, therefore reflecting a 
possible combination of the two proposed insult pathways [39]. A trigger such as 
LA or as described by Brookes et al. ischemia/reperfusion might lead to a 
mitochondrial Ca2+ overload, mitochondrial dysfunction, production of ROS, 
which exacerbates mitochondrial damage [39]. 
Cytotoxic effects of LA have been described in several studies, however, 
without elucidation of the underlying mechanism [40-42]. Park et al. have shown 
increased ROS concentration correlating with cell death of Schwann cells after 
incubation with bupivacaine [43]. The authors thereby suggested a ROS-
triggered caspase-3-activated apoptosis in neuronal cells. These conclusions 
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were supported by results from Perez-Castro, which showed a caspase-3/-7 
activation in human neuroblastoma cells after 10-minutes incubation with 
lidocaine, ropivacaine and bupivacaine [44]. In our study, ROS concentrations 
increased upon exposure to lidocaine and bupivacaine, while at the same time 
caspase-3 activity was not influenced. Therefore, the pathway of ROS-induced 
apoptosis in our model with lidocaine and bupivacaine is rather unlikely. 
Regarding ropivacaine cytotoxicity, the mechanism of ropivacaine–induced cell 
impairment still remains unclear and needs further evaluation. 
If the cytotoxic effect is related to Na channel blocking is rather 
questionable. LA are well known to interact not only with Na-, but also with K- 
and Ca channels [45]. In addition, they interfere with Ca uptake and release from 
the endoplasmic reticulum [46]. Data are also indicating that LA modify N-methyl-
D-aspartate (NMDA) receptor function [47]. All these and probably many more 
unknown interactions lead to a variety of properties of LA such as myotoxicity 
[46], anti-inflammatory [13], anti-microbial [48], and anti-cancerogenic effects 
[49], which cannot be attributed to their well-known action on Na channels. 
These in vitro data could lead to the assumption that certain local 
anesthetics might have similar effects in vivo, especially by using perineural 
continuous application of local anesthetic or wound instillation leading to tissue 
LA concentrations over several days, a factor which seems to be crucial for 
cytotoxicity according to our results. Though, we must bear in mind that the in 
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vitro model is a limitation of this study, using a cell line. Despite the toxic effects 
observed with these concentrations, further clinical studies are needed to support 
the present findings in vivo. Furthermore, perineural catheters for regional 
anesthesia and pain therapy are worldwide used. Prospective studies with large 
numbers of patient did not report significant clinical neurotoxic-related 
complications [50-52]. However, wound healing was not assessed in detail. If 
neuronal cytotoxicity of LA and cytotoxicity of LA on fibroblasts is comparable 
remains questionable. Neuronal cells do not proliferate, while fibroblasts are 
highly active during the phase of wound healing. Therefore, no direct conclusions 
can be drawn from all theses prospective analysis. Additionally, the average 
duration of the catheter was in these studies shorter, 56 hours and 3.0 to 4.7 
days, respectively [50,52]. 
The real clinical impact of this study warrants further investigations. 
However, it seems advisable to limit continuous application of LA for no more 
than 72-92 hours, to use the lowest effective concentration and to choose the 
least cytotoxic LA. Application of these techniques in patients with reduced tissue 
healing (e.g. diabetics, smokers) need to be carefully investigated. 
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A: Change of cell count after an incubation of 2 days with lidocaine, bupivacaine 
and ropivacaine with a concentration of 0.3 mg/ml (group 1), assessed after 3, 6 
and 9 days. Values are mean ± SD. 
B: Change of cell count after an incubation of 2 days with lidocaine, bupivacaine 
and ropivacaine with a concentration of 0.6 mg/ml (group 1), assessed after 3, 6 
and 9 days. Values are mean ± SD. 
C: Change of cell count after an incubation with lidocaine, bupivacaine and 
ropivacaine for 3, 6 and 9 days (group 2) with a concentration of 0.3 mg/ml, 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
D: Change of cell count after an incubation with lidocaine, bupivacaine and 
ropivacaine for 3, 6 and 9 days (group 2) with a concentration of 0.6 mg/ml, 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
 
Figure 2 
A: Change of viability after an incubation of 2 days with lidocaine, bupivacaine 
and ropivacaine with a concentration of 0.3 mg/ml (group 1), assessed after 3, 6 
and 9 days. Values are mean ± SD.  
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B: Change of viability after an incubation of 2 days with lidocaine, bupivacaine 
and ropivacaine with a concentration of 0.6 mg/ml (group 1), assessed after 3, 6 
and 9 days. Values are mean ± SD.  
C: Change of viability after an incubation with lidocaine, bupivacaine and 
ropivacaine for 3, 6 and 9 days (group 2) with a concentration of 0.3 mg/ml, 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
D: Change of viability after an incubation with lidocaine, bupivacaine and 
ropivacaine for 3, 6 and 9 days (group 2) with a concentration of 0.6 mg/ml, 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
 
Figure 3 
A: Change of proliferation rate after an incubation of 2 days with lidocaine, 
bupivacaine and ropivacaine with a concentration of 0.3 mg/ml (group 1), 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
B: Change of proliferation rate after an incubation of 2 days with lidocaine, 
bupivacaine and ropivacaine with a concentration of 0.6 mg/ml (group 1), 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
C: Change of proliferation rate after an incubation with lidocaine, bupivacaine 
and ropivacaine for 3, 6 and 9 days (group 2) with a concentration of 0.3 mg/ml, 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
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D: Change of proliferation rate after an incubation with lidocaine, bupivacaine 
and ropivacaine for 3, 6 and 9 days (group 2) with a concentration of 0.6 mg/ml, 
assessed after 3, 6 and 9 days. Values are mean ± SD.  
 
Figure 4 
A: Change of apoptosis rate after an incubation of 2 days with lidocaine, 
bupivacaine and ropivacaine with a concentration of 0.3 mg/ml (group 1), 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
B: Change of apoptosis rate after an incubation of 2 days with lidocaine, 
bupivacaine and ropivacaine with a concentration of 0.6 mg/ml (group 1), 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
C: Change of apoptosis rate after an incubation with lidocaine, bupivacaine and 
ropivacaine for 3, 6 and 9 days (group 2) with a concentration of 0.3 mg/ml, 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
D: Change of apoptosis rate after an incubation with lidocaine, bupivacaine and 
ropivacaine for 3, 6 and 9 days (group 2) with a concentration of 0.6 mg/ml, 
assessed after 3, 6 and 9 days. Values are mean ± SD. 
 
Figure 5 
A: Production of reactive oxygen species. Fibroblasts were incubated for 5 hours 
with lidocaine, bupivacaine and ropivacaine in concentrations of 0.3 mg/ml, 0.6 
 30 
mg/ml and 1.25 mg/ml. Reactive oxygen species were determined. Values are 
mean ± SD. 
B: Determination of viability (control = 100%). Fibroblasts were incubated for 5 
hours with lidocaine, bupivacaine and ropivacaine in concentrations of 0.3 mg/ml, 
0.6 mg/ml and 1.25 mg/ml. Cell viability was determined. Values are mean ± SD. 
 
Figure 6 
Correlation analysis. Production of reactive oxygen species was assessed and 
correlated to cell viability after incubation with lidocaine (A) and bupivacaine (B).  
 
 
 
